Electronic Pharmacy Information Coverage database and DARE were searched from inception to September 2005. Search terms were reported. In addition, reference lists of reviews and included studies were screened and citations of key papers were tracked. Only studies published in English were included.
Study selection
Randomised controlled trials that evaluated the effect of pharmacist-led medication review in older people (mean age >60 years) with a range of diseases were eligible for inclusion. Trials had to be delivered by a pharmacist and have a follow-up period of one month or more. The primary review outcome was the proportion of patients with one or more hospital emergency admissions for any cause. Secondary outcomes were all-cause mortality and the mean number of drugs prescribed.
Most trials were conducted in hospital or clinic/primary care settings and most were conducted in the UK or USA. Trials involved a variety of different types of pharmacist (hospital or clinical, specialist or research and community). Half of the trials involved a single pharmacist.
Two reviewers independently selected studies and resolved disagreements by discussion with the help of a third reviewer if required.
Assessment of study quality
The following ten validity-related items were extracted by one reviewer and checked by a second reviewer: allocation concealment; intention-to-treat analysis; outcome data verified using more than one source; inclusion criteria explicitly defined; baseline comparability of treatment groups; clearly defined primary outcome; sample size calculation; length of follow-up at least six months; over 80% of patients retained; and training and selection of pharmacists reported.
Data extraction
Outcome data were extracted at the last pre-specified follow-up point by one reviewer and checked by a second reviewer. Data included the number of events in each group for dichotomous outcomes and means and standard deviations for continuous outcomes.
Methods of synthesis
Pooled relative risks and weighted mean differences with 95% confidence intervals for pharmacist-led interventions compared with usual care were calculated using random-effects models. Heterogeneity was assessed using the χ 2 and the I 2 statistics. If significant heterogeneity was present, analyses were repeated using a fixed-effect model. Sensitivity analysis was undertaken by excluding poorer quality trials and by examining the effect of intervention characteristics (type of pharmacist, level of patient contact and intensity of intervention). Publication bias was assessed using a funnel plot.
